Skip to main content

Table 3 Efficacy comparison of different first-line treatments based on a tumour assessment

From: Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment

Tumour assessment First-line treatment P value
1-CRZ(n = 32) 1-PP(n = 28) N1-PP(n = 13)
Type of response, n %     
 Complete response 1 (3.1) 0 (0) 0 (0)  
 Partial response 24 (75.0) 5 (17.9) 2 (15.4)  
 Stable disease 7 (21.9) 11 (39.3) 4 (30.8)  
 Progressive disease 0 (0) 9 (32.1) 6 (46.1)  
 Not evaluable 0 (0) 3 (10.7) 1 (7.7)  
 ORR(%) 78.1 17.9 15.4 <0.001
 DCR(%) 100.0 57.2 46.2 <0.001
  1. Note. — Unless otherwise indicated, the data are shown as numbers with percentages in parentheses. The statistical analysis for DCR and ORR were performed using the Chi-Square test